Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
| Autor: | Puig-Domingo, Manuel, Soto, Alfonso, Venegas, Eva, Vilchez, Ricardo, Blanco, Concepción, Cordido, Fernando, Lucas, Tomás, Marazuela, Mónica, Casany, Rosa, Cuatrecasas, Guillem, Fajardo, Carmen, Gálvez, María Ángeles, Maraver, Silvia, Martín, Tomás, Romero, Enrique, Paja, Miguel, Picó, Antonio, Bernabeu, Ignacio, Resmini, Eugenia, ACROCOMB study group |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Cabergoline Análogos de la somatostatina Combination therapy Endocrinology Diabetes and Metabolism Cabergolina Pegvisomant 030209 endocrinology & metabolism Somatostatin analogues Lanreotide Peptides Cyclic Gastroenterology Acromegalia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Lanreotida Internal medicine Acromegaly Humans Medicine 030212 general & internal medicine Ergolines Insulin-Like Growth Factor I Retrospective Studies Human Growth Hormone business.industry Retrospective cohort study medicine.disease IGF-I Somatostatin chemistry Dopamine Agonists Cohort Drug Therapy Combination business medicine.drug |
| Zdroj: | RUC. Repositorio da Universidade da Coruña instname Endocrinologia y Nutricion r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau r-FISABIO. Repositorio Institucional de Producción Científica r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante |
| ISSN: | 1575-0922 |
| Popis: | [Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly. PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy between 2006 and 2011. 108 patients treated at 44 Spanish Endocrinology Departments were analyzed separately: 61 patients received lanreotide/cabergoline (cabergoline cohort) and 47 lanreotide/pegvisomant (pegvisomant cohort). RESULTS: Patient median age was 50.8 years in the cabergoline cohort and 42.7 years in the pegvisomant cohort. Prior medical treatments were somatostatin analogue (SSA) monotherapy (40 [66%] patients) or dopamine agonists (7 [11%] patients) in the cabergoline cohort and SSA (29 [62%] patients) or pegvisomant monotherapy (16 [34%] patients) in the pegvisomant cohort. Across both cohorts 12 patients were previously untreated, and prior therapy was unknown/missing in 4 patients. Median duration of combined treatment was 1.6 years (0.1-6) and 2.1 years (0.4-6.3) in the cabergoline and pegvisomant cohorts, respectively. At baseline, median insulin growth factor (IGF)-I values were 149% upper limit of normal (ULN) (15-505%) in the cabergoline cohort and 156% ULN (15-534%) in the pegvisomant cohort, and decreased to 104% ULN (13-557%) p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|